1. Medtech Insight
  2. >>Device Area

I Think, Therefore I Write: Breakthrough Device Turns Thoughts Into Words

 
• By Brian Bossetta

Blackrock Neurotech’s MoveAgain technology platform allows patients who have been silenced by ALS, paralysis and other spinal cord injuries the ability to better communicate via text. The device has been granted breakthrough status by the US FDA.

AI chipset with human brain on computer circuit board.
• Source: Alamy

Most people take the ability to communicate for granted, but for the nearly 5 million people who can’t because of spinal cord injury or disease, it’s a gift that has been taken away. A new technology from Blackrock Neurotech, however, aims to help these patients by giving them a faster way to communicate by turning their thoughts into words.

The company’s MoveAgain Brain Computer Interface (BCI) System, which provides immobile patients the ability to control mobile devices, cursors, and keyboards using only their mind, was recently given breakthrough device...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurology

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.